A commercial comparator formulation used in the study produced nerve blocks lasting approximately four to eight hours. A new injectable formulation kept rats’ sciatic nerves blocked for up to two to three weeks. The difference is not the drug; it is the container.
Researchers at Boston Children’s Hospital and Harvard Medical School, led by Yuan Wang, PhD, and Daniel S. Kohane, MD, PhD, published the findings Sept. 23, 2026, in Nature Biomedical Engineering. This is preclinical work conducted in rats, not an available treatment or an approved anesthetic.
How the Liposomes Work
The counterintuitive architecture behind ultra-slow drug release.
Liposomes are microscopic spheres built from lipid membranes. Researchers have used them as drug-delivery vehicles for decades, and their composition controls how quickly an encapsulated drug escapes.
The conventional assumption held that more-fluid lipid membranes release water-soluble drugs faster. Wang and Kohane’s team found the opposite, under specific conditions.
When they built liposomes from highly unsaturated phospholipids, those lipids did not form a single simple sphere. They self-assembled into multiple nested compartments, one inside another. Think of the structure as an analogy to Russian matryoshka dolls: each layer adds another wall between the drug and surrounding tissue.
Each membrane a hydrophilic molecule must cross slows its exit. More compartments can create a longer path out, which the researchers proposed produces a slower, more sustained release into nerve tissue.
The drug loaded into the liposomes was tetrodotoxin, the neurotoxin found in pufferfish and blue-ringed octopuses, which blocks nerve signaling at very small doses. Here is what the rat experiments showed across dose levels, according to the Nature Biomedical Engineering study:
- 80 micrograms: median return of sensation around 6.5 days
- 200 micrograms: median around 11 days
- 260 micrograms: median around 13 days, with full sensation returning over roughly two to three weeks
- No local or systemic toxicity observed in tested animals at those doses
- Commercial comparator formulation: approximately four to eight hours of nerve block
Those figures represent median recovery milestones, not necessarily continuous full anesthesia across the entire period.
What This Could Mean (and What It Doesn’t)
A promising delivery platform, still a long road from a patient’s care plan.
Kohane told news-medical.net that the approach could support longer-term perioperative pain control as an alternative to opioids, and that the team was beginning to consider chronic pain applications. He also noted the liposome platform could potentially deliver a broad range of other hydrophilic molecules, a secondary implication researchers consider significant.
Tetrodotoxin, however, remains a potent neurotoxin. The absence of toxicity in these rat experiments reflects the specific delivery system and experimental conditions tested, not a general safety clearance for clinical use. No approval for tetrodotoxin as a patient anesthetic was identified in the sources reviewed, and any human development would require regulatory review.
If this approach eventually reaches human trials and clears safety review, it could change how surgical teams manage post-operative pain without opioids. That step remains distant. Translating this finding would require extensive additional work. Long-term toxicology, dose optimization, immune response studies, manufacturing development, and carefully controlled human trials would all be necessary before any clinical application.
No independent replication was identified in the sources reviewed. What the Boston Children’s team has demonstrated is a meaningful advance in controlled-release drug delivery. Independent replication and early-phase human safety trials are the markers worth watching next.
